In conclusion, these data show that GDC-0941 has broad anti-proliferative activity amongst many tumor types represented in the NCI-60 cell panel, suggesting its clinical utility against multiple tumor types, and that a number of tumor cell lines with activated AKT1 are highly sensitive to inhibition of PI3K with GDC-0941. This evidence concerns the gene PIK3CA and neoplasm.